CVS
CVS HEALTH CorpEvidence as of 2026-09-02Overview · CVS HEALTH Corp
CVS Health Corporation provides health services in the United States. It operates through Health Care Benefits, Pharmacy Services, and Retail/LTC segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, gover…
Management team
- Mr. Prem S. Shah Pharm.D · Executive VP & Group PresidentFind on LinkedIn
- Ms. Heidi B. Capozzi · Executive VP & Chief People OfficerFind on LinkedIn
- Mr. Tilak Mandadi · EVP of Ventures and Chief Experience & Technology OfficerFind on LinkedIn
- Mr. Thomas Francis Cowhey · Executive VP & CFOFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.6 on a −2 to +2 scale — was +0.7 before the debate changed the read.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The desk rates the evidence balance as Constructive (+0.6 of a possible +2; was +0.7 before the debate). Revenues increased from $100,426,000,000 in fiscal Q1 2026 (fiscal quarter ended 2026-04-29) to $106,096,000,000 in fiscal Q2 2026 (fiscal quarter ended 2026-07-29). Net income moved from $2,943,000,000 to $2,979,000,000 across those quarters while diluted EPS held effectively flat at $2.30 and $2.31.
Cash and cash equivalents rose from $9,542,000,000 as of 2026-03-31 to $11,329,000,000 as of 2026-06-30, operating income was roughly unchanged at about $4,680,000,000 to $4,703,000,000, and entity common shares outstanding ticked higher from 1,272,211,063 to 1,278,970,369 on the point-in-time readings supplied. Market metrics show strong medium-term momentum (12_1 = +75.0%, 90th percentile) and a golden‑cross technical flag, while valuation reads mixed — price-to-FCF of 7.03 with FCF ttm of $17,865,000,000 versus a trailing P/E of 42.81 and EV/EBITDA of 13.93.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenues rose from $100,426,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) to $106,096,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0000064803-26-000052Net income (loss) was $2,943,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $2,979,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo), a small quarter-over-quarter increase.
XBRL companyfacts · 0000064803-26-000052Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
On August 13, 2026, Larry M. Robbins resigned from the Board of Directors of CVS Health Corporation, and the company stated his resignation "was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company."
8-K filed 2026-08-17On August 17, 2026, the Board appointed Teresa Heitsenrether to the Board, with an effective service commencement date of November 18, 2026.
8-K filed 2026-08-17Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum (12_1) is +75.0% and CVS ranks in the 90th percentile of the 547‑company research universe for that metric as of 2026-09-01.
Moneyta signal set · 2026-09-01weakened in debatePrice is -3.2% vs the 50‑day SMA but +14.4% vs the 200‑day SMA as of 2026-09-01, and a golden cross flag is true on that date.
Moneyta signal set · 2026-09-01Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T01:55:42.883348+00:00, CVS appears in the XLV ETF with a reported weight of 1.78% of that fund.
ETF constituents · market dataAs of 2026-09-01T19:40:19.315712+00:00, CVS appears in the IVV ETF with a reported weight of 0.20% of that fund.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Several outlets ran headlines on 1–2 September 2026 noting a stock rally or renewed investor interest in CVS after a corporate update and sector conditions were discussed.
News · finance.yahoo.com · 2026-09-01A syndicated headline on 1 September 2026 framed CVS as 'in focus' following a corporate update and referenced sector and broader market themes in explaining the attention.
News · kalkinemedia.com · 2026-09-01Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model calculates an implied free-cash-flow (FCF) growth rate of -14.44% that today's price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closePrice-to-FCF (price_to_fcf) is 7.03 and FCF on a trailing twelve-month basis (fcf_ttm) is $17,865,000,000, which corresponds to FCF per share of $13.8811.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several pieces of the provided evidence jointly support a favorable read: quarter-to-quarter revenue and net income increases, a rise in cash on the balance sheet, and steady operating income point to stable operational performance (fundamentals-0, fundamentals-1, fundamentals-4, fundamentals-5). Trailing cash-flow metrics and valuation signals — a low price-to-FCF of 7.03 and positive free-cash-flow on a TTM basis — strengthen the cash-generation narrative relative to an earnings-based multiple divergence (valuation-1, valuation-5, valuation-2). Market indicators (strong short- and medium-term momentum, a golden-cross flag, low beta, and inclusion in multiple ETFs) show renewed investor interest and lower measured market sensitivity that accompany the fundamental and cash-flow picture (market-0, market-1, market-2, market-4, ownership-3). These items together rebut the bear framing that focuses on headline drawdowns or an earnings multiple disconnect by emphasizing cash-flow strength, improving recent momentum, and institutional/ETF ownership supporting liquidity and investor attention.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.38
35 surviving claims rest on 13 distinct sources; the heaviest analyst carries 20% of them, and 97% of what the desk raised survived the debate.
The read rests on a moderate breadth of sources but a meaningful share of claims trace back to a small number of contributors; the heaviest analyst supplying one fifth of surviving claims raises analyst-dependence risk. A 97% survival rate through debate means the desk's claims were rarely overturned, which increases internal consistency but also suggests the set faced limited disconfirming challenge — treat the bundle as coherent but not heavily stress‑tested.
Peer context · computed, not argued
12-1 momentum ranks 2nd of 4 in Healthcare Plans (as of 2026-09-01).
dividend yield ranks 1st of 4 in Healthcare Plans (as of 2026-09-01).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
17 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.3 to the score
2 documents
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.5 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.7 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+1.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on CVS Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.